Published in Biochim Biophys Acta on November 18, 2009
Clonal evolution in cancer. Nature (2012) 11.07
Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48
Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol (2011) 7.84
Cells of origin in cancer. Nature (2011) 6.85
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 5.68
Defining the mode of tumour growth by clonal analysis. Nature (2012) 5.02
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer (2010) 4.19
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep (2014) 3.24
Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol (2010) 3.02
Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature (2014) 2.91
Heterogeneity in breast cancer. J Clin Invest (2011) 2.86
Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature (2014) 2.75
Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 2.56
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb Perspect Biol (2010) 2.03
Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 1.99
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med (2015) 1.98
Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing. Virchows Arch (2014) 1.93
Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin (2013) 1.83
Metabolic trade-offs and the maintenance of the fittest and the flattest. Nature (2011) 1.82
Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc Natl Acad Sci U S A (2011) 1.76
High-throughput sequencing for biology and medicine. Mol Syst Biol (2013) 1.75
Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70
Targeted enrichment of genomic DNA regions for next-generation sequencing. Brief Funct Genomics (2011) 1.63
Inferring clonal evolution of tumors from single nucleotide somatic mutations. BMC Bioinformatics (2014) 1.62
Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett (2012) 1.58
Tracing the tumor lineage. Mol Oncol (2010) 1.56
Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer (2012) 1.44
Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents. PLoS One (2015) 1.44
Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol (2012) 1.40
Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med (2013) 1.39
Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization. Cancer Res (2012) 1.28
Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging (2011) 1.27
Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc Natl Acad Sci U S A (2015) 1.24
Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci U S A (2012) 1.21
Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol (2011) 1.18
Leading malignant cells initiate collective epithelial cell invasion in a three-dimensional heterotypic tumor spheroid model. Clin Exp Metastasis (2013) 1.18
PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol (2015) 1.17
Breast cancer intra-tumor heterogeneity. Breast Cancer Res (2014) 1.16
Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 1.15
Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles. Radiology (2014) 1.12
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun (2016) 1.08
Exposome informatics: considerations for the design of future biomedical research information systems. J Am Med Inform Assoc (2013) 1.07
Evolutionary game theory of growth factor production: implications for tumour heterogeneity and resistance to therapies. Br J Cancer (2013) 1.07
Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol (2015) 1.06
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget (2015) 1.02
Are cancer stem cells radioresistant? Future Oncol (2010) 1.01
The problem of colliding networks and its relation to cell fusion and cancer. Biophys J (2012) 1.00
Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. Int J Radiat Oncol Biol Phys (2013) 1.00
Extracellular Vesicles: Satellites of Information Transfer in Cancer and Stem Cell Biology. Dev Cell (2016) 0.99
Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc Natl Acad Sci U S A (2011) 0.99
Tumor heterogeneity and its implication for drug delivery. J Control Release (2012) 0.99
Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel) (2014) 0.99
Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS One (2012) 0.99
Gene signatures of breast cancer progression and metastasis. Breast Cancer Res (2011) 0.99
Algorithms to model single gene, single chromosome, and whole genome copy number changes jointly in tumor phylogenetics. PLoS Comput Biol (2014) 0.98
High DNA methylation pattern intratumoral diversity implies weak selection in many human colorectal cancers. PLoS One (2011) 0.98
Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. BMC Genomics (2013) 0.98
Human correlates of provocative questions in pancreatic pathology. Adv Anat Pathol (2012) 0.97
Quantum dots as a platform for nanoparticle drug delivery vehicle design. Adv Drug Deliv Rev (2012) 0.97
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer. Front Oncol (2015) 0.97
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol (2012) 0.97
From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity. Oncotarget (2015) 0.96
A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma. Mol Cell Biol (2012) 0.95
Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol (2012) 0.93
Endosialin expression in side populations in human sarcoma cell lines. Oncol Lett (2011) 0.92
Dissecting social cell biology and tumors using Drosophila genetics. Annu Rev Genet (2013) 0.92
Predicting pathologic tumor response to chemoradiotherapy with histogram distances characterizing longitudinal changes in 18F-FDG uptake patterns. Med Phys (2013) 0.91
Illuminating breast cancer invasion: diverse roles for cell-cell interactions. Curr Opin Cell Biol (2014) 0.91
New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res (2011) 0.90
Zebrafish as a model to assess cancer heterogeneity, progression and relapse. Dis Model Mech (2014) 0.90
Estimating dose painting effects in radiotherapy: a mathematical model. PLoS One (2014) 0.90
A mammosphere formation RNAi screen reveals that ATG4A promotes a breast cancer stem-like phenotype. Breast Cancer Res (2013) 0.89
Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system. PLoS One (2012) 0.89
Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. Clin Exp Metastasis (2011) 0.89
Heterogeneous kinetics of AKT signaling in individual cells are accounted for by variable protein concentration. Front Physiol (2012) 0.89
Higher gene expression variability in the more aggressive subtype of chronic lymphocytic leukemia. Genome Med (2015) 0.89
A robust method to analyze copy number alterations of less than 100 kb in single cells using oligonucleotide array CGH. PLoS One (2013) 0.88
Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing. Oncotarget (2012) 0.88
The mini-driver model of polygenic cancer evolution. Nat Rev Cancer (2015) 0.87
Tumor-specific chromosome mis-segregation controls cancer plasticity by maintaining tumor heterogeneity. PLoS One (2013) 0.87
Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single-cell resolution. FASEB J (2013) 0.87
How cancer shapes evolution, and how evolution shapes cancer. Evolution (N Y) (2011) 0.87
Positive expression of NANOG, mutant p53, and CD44 is directly associated with clinicopathological features and poor prognosis of oral squamous cell carcinoma. BMC Oral Health (2015) 0.86
Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers. Antioxid Redox Signal (2014) 0.86
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
Omics Profiling in Precision Oncology. Mol Cell Proteomics (2016) 0.85
Cancer stem cells - the current status of an old concept: literature review and clinical approaches. Biol Res (2014) 0.85
Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication. World J Biol Chem (2015) 0.85
Correlation between plasma DNA and tumor status in an animal model. PLoS One (2014) 0.85
Cell-free circulating tumor DNA in cancer. Chin J Cancer (2016) 0.85
Keeping an open mind: highlights and controversies of the breast cancer stem cell theory. Breast Cancer (Dove Med Press) (2012) 0.84
Applying ecological and evolutionary theory to cancer: a long and winding road. Evol Appl (2012) 0.84
Progress in understanding melanoma propagation. Mol Oncol (2010) 0.84
The hallmarks of cancer. Cell (2000) 113.05
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
The evolution of cooperation. Science (1981) 32.89
The epigenomics of cancer. Cell (2007) 30.91
The clonal evolution of tumor cell populations. Science (1976) 24.39
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Bacterial persistence as a phenotypic switch. Science (2004) 15.80
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Tumor growth need not be driven by rare cancer stem cells. Science (2007) 10.34
Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Intrinsic tumour suppression. Nature (2004) 8.73
Adaptive radiation in a heterogeneous environment. Nature (1998) 8.44
Systemic spread is an early step in breast cancer. Cancer Cell (2008) 7.91
Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med (1995) 7.37
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature (2006) 7.35
Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci U S A (1975) 7.27
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature (2009) 7.24
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2004) 6.92
Stem cell concepts renew cancer research. Blood (2008) 6.74
Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 6.71
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Tumor heterogeneity. Cancer Res (1984) 6.17
Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol (2007) 6.08
Rac activation and inactivation control plasticity of tumor cell movement. Cell (2008) 6.01
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev (2004) 5.83
Seeding and propagation of untransformed mouse mammary cells in the lung. Science (2008) 5.33
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A (2003) 4.79
Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A (2003) 4.47
A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell (2005) 4.32
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH. Genome Res (2003) 4.10
Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res (1997) 4.02
Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95
Biological diversity in metastatic neoplasms: origins and implications. Science (1982) 3.95
Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A (1999) 3.74
Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell (2005) 3.67
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet (2002) 3.45
Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A (2006) 3.32
Chemical warfare between microbes promotes biodiversity. Proc Natl Acad Sci U S A (2002) 3.15
Co-evolution of tumor cells and their microenvironment. Trends Genet (2008) 3.08
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell (2008) 3.01
Structure of the intermediates leading to the integrated provirus. Biochim Biophys Acta (1977) 2.96
Adaptive therapy. Cancer Res (2009) 2.81
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73
Dynamics of cancer progression. Nat Rev Cancer (2004) 2.64
Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A (2006) 2.63
Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol (2008) 2.38
Identifying cancer stem cells in solid tumors: case not proven. Cancer Res (2006) 2.28
The importance of being persistent: heterogeneity of bacterial populations under antibiotic stress. FEMS Microbiol Rev (2009) 2.23
Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science (1996) 2.22
Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci U S A (2002) 2.17
An evolutionary model of carcinogenesis. Cancer Res (2003) 2.10
The influence of the microenvironment on the malignant phenotype. Mol Med Today (2000) 2.08
Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat (2006) 2.04
Cancer selection. Nat Rev Cancer (2003) 1.99
Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc Natl Acad Sci U S A (2009) 1.98
Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics (2008) 1.95
Molecular evolutionary clock and the neutral theory. J Mol Evol (1987) 1.90
Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol (1998) 1.84
Evidence for multiple adaptive peaks from populations of bacteria evolving in a structured habitat. Proc Natl Acad Sci U S A (1994) 1.76
Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res (1998) 1.74
Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry (1988) 1.72
TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res (2004) 1.70
Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol (1994) 1.64
Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol (1996) 1.64
Genetic divergence in the clonal evolution of breast cancer. Cancer Res (1996) 1.63
Evolutionary biology of cancer. Trends Ecol Evol (2005) 1.58
The fuzzy math of solid tumor stem cells: a perspective. Cancer Res (2007) 1.56
Fetal microchimerism in women with breast cancer. Cancer Res (2007) 1.55
Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle (2006) 1.54
Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol (2008) 1.51
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood (2003) 1.50
Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology (1994) 1.48
Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer (2002) 1.45
Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res (2000) 1.43
Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell (2004) 1.41
Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res (1996) 1.40
Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res (2004) 1.40
Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A (1987) 1.36
Game-theory models of interactions between tumour cells. Eur J Cancer (1997) 1.35
Clonal heterogeneity in breast cancer: karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients. Int J Cancer (1995) 1.30
A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. Exp Hematol (2002) 1.30
A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res (2001) 1.29
Positive interactions among competitors can produce species-rich communities. Ecol Lett (2008) 1.29
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Ductal carcinoma in situ of the breast. N Engl J Med (2004) 6.63
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A (2002) 4.45
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet (2005) 4.33
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet (2008) 3.32
Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res (2010) 3.19
Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med (2005) 3.19
Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle (2007) 3.01
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol (2012) 2.56
Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res (2003) 2.55
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res (2009) 2.37
Microenvironmental regulation of cancer development. Curr Opin Genet Dev (2008) 2.25
The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res (2011) 2.22
DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer (2003) 2.18
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell (2009) 2.15
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01
Genetic and phenotypic diversity in breast tumor metastases. Cancer Res (2014) 1.96
Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res (2008) 1.82
Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A (2009) 1.81
Identifying tumor origin using a gene expression-based classification map. Cancer Res (2003) 1.78
The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell (2013) 1.75
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res (2006) 1.74
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell (2013) 1.73
RNA sequencing of cancer reveals novel splicing alterations. Sci Rep (2013) 1.57
The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila) (2010) 1.55
PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res (2010) 1.49
Cancer stem cells: a model in the making. Curr Opin Genet Dev (2009) 1.48
The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest (2008) 1.47
A neural survival factor is a candidate oncogene in breast cancer. Proc Natl Acad Sci U S A (2003) 1.41
Gene expression profiling of human breast tissue samples using SAGE-Seq. Genome Res (2010) 1.41
Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer (2008) 1.39
Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res (2002) 1.35
Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res (2004) 1.35
Stem cells in the human breast. Cold Spring Harb Perspect Biol (2010) 1.33
Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res (2008) 1.31
Cancer chromosomes in crisis. Nat Genet (2004) 1.30
Psoriasin expression in mammary epithelial cells in vitro and in vivo. Cancer Res (2002) 1.29
Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene (2002) 1.27
Origin of carcinoma associated fibroblasts. Cell Cycle (2009) 1.22
Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Res (2009) 1.21
A putative role for psoriasin in breast tumor progression. Cancer Res (2005) 1.19
Epigenetic regulation of cell type-specific expression patterns in the human mammary epithelium. PLoS Genet (2011) 1.15
PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One (2010) 1.15
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell (2013) 1.14
Epigenetic patterns of embryonic and adult stem cells. Cell Cycle (2009) 1.13
HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res (2005) 1.13
Breast-cancer stromal cells with TP53 mutations. N Engl J Med (2008) 1.10
Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res (2004) 1.10
Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin Cancer Res (2004) 1.10
Altered antisense-to-sense transcript ratios in breast cancer. Proc Natl Acad Sci U S A (2010) 1.08
Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosomes Cancer (2012) 1.06
Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res (2013) 1.06
The challenges posed by cancer heterogeneity. Nat Biotechnol (2012) 1.05
The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci U S A (2011) 1.02
Cancer. Cancer cell phenotypes, in fifty shades of grey. Science (2013) 1.02
Targeting the missing links for cancer therapy. Nat Med (2011) 0.99
Psoriasin (S100A7) and calgranulin-B (S100A9) induction is dependent on reactive oxygen species and is downregulated by Bcl-2 and antioxidants. Cancer Biol Ther (2005) 0.98
Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest (2009) 0.98
S100A7-downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation. PLoS One (2008) 0.97
Expression of high in normal-1 (HIN-1) and uteroglobin related protein-1 (UGRP-1) in adult and developing tissues. Mech Dev (2002) 0.97
Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors. Cancer Res (2003) 0.91
Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis. J Pathol (2013) 0.90
Serial analysis of gene expression. Nat Protoc (2006) 0.88
Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res (2008) 0.88
Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res (2008) 0.87
Deconvoluting complex tissues for expression quantitative trait locus-based analyses. Philos Trans R Soc Lond B Biol Sci (2013) 0.87
A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Res (2012) 0.87
SAGE and related approaches for cancer target identification. Drug Discov Today (2006) 0.86
Methylation-specific digital karyotyping. Nat Protoc (2006) 0.84
Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. Cancer Res (2011) 0.83
Tracking tumor resistance using 'liquid biopsies'. Nat Med (2013) 0.82
Cancer target discovery using SAGE. Expert Opin Ther Targets (2003) 0.81
Serial analysis of gene expression (SAGE): experimental method and data analysis. Curr Protoc Mol Biol (2007) 0.80
The expression of Psoriasin (S100A7) and CD24 is linked and related to the differentiation of mammary epithelial cells. PLoS One (2012) 0.80
Tumor heterogeneity: the Lernaean hydra of oncology? Oncology (Williston Park) (2014) 0.80
Unraveling the complexity of basal-like breast cancer. Oncotarget (2011) 0.79
EMSY links breast cancer gene 2 to the 'Royal Family'. Breast Cancer Res (2004) 0.79
Serial analysis of gene expression (SAGE): experimental method and data analysis. Curr Protoc Hum Genet (2007) 0.76
Going small is the new big. Nat Methods (2010) 0.75